Skip to main content
SynAct Pharma logo

SynAct Pharma — Investor Relations & Filings

Ticker · SYNACT ISIN · SE0008241491 LEI · 549300RRYIEFEQ72N546 ST Manufacturing
Open in API
Filings indexed 223 across all filing types
Latest filing 2023-11-22 AGM Information
Country SE Sweden
Listing ST SYNACT

About SynAct Pharma

https://synactpharma.com/en/

SynAct Pharma is a clinical-stage biotechnology company developing innovative medicines designed to resolve inflammation rather than solely inhibit it. The company's approach focuses on resolution therapy by leveraging melanocortin biology to restore immune balance. Its lead candidate, Resomelagon (AP1189), is a once-daily oral therapy that selectively activates melanocortin receptors on key immune cells. SynAct Pharma's development programs target a broad range of inflammatory conditions, including early intervention in chronic diseases to limit progression and the modulation of hyperinflammatory stages in acute viral diseases to reduce the risk of severe organ dysfunction.

Recent filings

Filing Released Lang Actions
Nomination Committee appointed ahead of AGM 2024 in SynAct Pharma AB
AGM Information Classification · 95% confidence The document explicitly discusses the appointment of the Nomination Committee in preparation for the Annual General Meeting (AGM) 2024. While it relates to the AGM, the core content is about the composition and duties of the Nomination Committee, which is a governance function. However, the primary subject is the preparation for the AGM itself, specifically concerning board nominations. The closest fit among the provided definitions is 'AGM Information (Code: AGM-R)' as it directly pertains to materials and announcements related to the Annual General Meeting. Although it touches upon governance (CGR), the context is strictly preparatory for the AGM event.
2023-11-22 English
Major Shareholding Notification 2023
Major Shareholding Notification Classification · 99% confidence The document details a change in shareholding for an individual named Thomas Jonassen concerning SynAct Pharma AB. It explicitly states the 'Reason for major shareholding notification Sell' and provides 'Before the transaction' and 'After the transaction' figures for shares and voting rights, including percentages. This structure is characteristic of a notification regarding a change in significant ownership thresholds. Based on the provided definitions, this aligns perfectly with the 'Major Shareholding Notification' category.
2023-11-15 English
Major Shareholding Notification 2023
Major Shareholding Notification Classification · 100% confidence The document is a regulatory filing from the Swedish Financial Supervisory Authority (Finansinspektionen) regarding a 'flaggningsmeddelande' (flagging notification). It details a change in shareholding by Ghita Vinter Øvlesen in SynAct Pharma AB, specifically noting a sale that reduced the holding below a 5% threshold. This is a classic major shareholding notification, which corresponds to the MRQ category.
2023-11-15 Swedish
Major Shareholding Notification 2023
Major Shareholding Notification Classification · 100% confidence The document is a regulatory filing from the Swedish Financial Supervisory Authority (Finansinspektionen) detailing a change in shareholding for SynAct Pharma AB. It explicitly lists the shareholder (Jeppe Øvli Øvlesen), the transaction type (sale), and the resulting change in ownership percentage (crossing below the 5% threshold). This is a standard major shareholding notification, which corresponds to the MRQ filing category.
2023-11-15 Swedish
Major Shareholding Notification 2023
Major Shareholding Notification Classification · 100% confidence The document is a 'flaggningsmeddelande' (flagging notification) filed with the Swedish Financial Supervisory Authority (Finansinspektionen). It details a change in shareholding for SynAct Pharma AB, specifically reporting that Thomas Jonassen's ownership has crossed a threshold (5%). This is a standard regulatory disclosure regarding major shareholding notifications.
2023-11-15 Swedish
Major Shareholding Notification 2023
Major Shareholding Notification Classification · 99% confidence The document details a change in shareholding for an individual, Ryan Quinn, in SynAct Pharma AB. It explicitly states the 'Reason for major shareholding notification Sell' and provides 'Before the transaction' and 'After the transaction' figures, including the resulting percentage of voting rights (4.217%). This structure is characteristic of a Major Shareholding Notification, where an investor reports crossing a threshold (in this case, falling below the 5% limit). This directly corresponds to the definition for Major Shareholding Notification (MRQ). The document length is relatively short (4540 chars), but the content is the notification itself, not an announcement of a report.
2023-11-06 English

Browse filings by year

5 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.